Kathleen Maguire-Zeiss

Neuroscience Georgetown University, Washington, DC 
Neuroscience Biology
"Kathleen Maguire-Zeiss"
Mean distance: 53433
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Winland CD, Welsh N, Sepulveda-Rodriguez A, et al. (2017) Inflammation alters AMPA-stimulated calcium responses in dorsal striatal D2 but not D1 spiny projection neurons. The European Journal of Neuroscience
Huang L, Shimoji M, Wang J, et al. (2013) Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 10: 840-51
Béraud D, Hathaway HA, Trecki J, et al. (2013) Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 8: 94-117
Feng LR, Maguire-Zeiss KA. (2011) Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance. Neurotoxicity Research. 20: 387-401
Khandelwal PJ, Dumanis SB, Feng LR, et al. (2010) Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model. Molecular Neurodegeneration. 5: 47
Lee BD, Shin JH, VanKampen J, et al. (2010) Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine. 16: 998-1000
Feng LR, Federoff HJ, Vicini S, et al. (2010) Alpha-synuclein mediates alterations in membrane conductance: a potential role for alpha-synuclein oligomers in cell vulnerability. The European Journal of Neuroscience. 32: 10-7
Maguire-Zeiss KA, Federoff HJ. (2010) Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 117: 1019-25
Feng LR, Maguire-Zeiss KA. (2010) Gene therapy in Parkinson's disease: rationale and current status. Cns Drugs. 24: 177-92
Su X, Federoff HJ, Maguire-Zeiss KA. (2009) Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotoxicity Research. 16: 238-54
See more...